It’s Tuesday and this is what I’m reading:
- Recalls happen every day and cost a lot of money, there is a way to insure against that financial loss, but few companies know about it or insure against it – Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets (Business Wire).
- 4 Regulations That Would Terrify U.S. Drug Companies Ahead Of The 2018 Midterms (Forbes).
- Another stark warning over CRISPR/Cas9’s potential to do lasting harm dents share prices (Endpoints).
- How medtech can prepare for the consequences of a “Hard Brexit” (Medical Design & Outsourcing).
MattCorc 